182 related articles for article (PubMed ID: 8070026)
21. Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
van Gijn R; ten Bokkel Huinink WW; Rodenhuis S; Vermorken JB; van Tellingen O; Rosing H; van Warmerdam LJ; Beijnen JH
Anticancer Drugs; 1999 Jan; 10(1):17-23. PubMed ID: 10194543
[TBL] [Abstract][Full Text] [Related]
22. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Shimada Y; Rothenberg M; Hilsenbeck SG; Burris HA; Degen D; Von Hoff DD
Anticancer Drugs; 1994 Apr; 5(2):202-6. PubMed ID: 8049503
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
24. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
McDonald AC; Brown R
Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
[TBL] [Abstract][Full Text] [Related]
25. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
[TBL] [Abstract][Full Text] [Related]
26. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
[TBL] [Abstract][Full Text] [Related]
28. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
29. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
30. Clinical use of topoisomerase I inhibitors in anticancer treatment.
Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
[TBL] [Abstract][Full Text] [Related]
31. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase I inhibitors: review and update.
Rothenberg ML
Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
34. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
35. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
36. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
38. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
39. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
[TBL] [Abstract][Full Text] [Related]
40. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Lamond JP; Mehta MP; Boothman DA
J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
